share_log

BioVie | 8-K/A: Current report (Amendment)

BioVie | 8-K/A: Current report (Amendment)

BioVie | 8-K/A:重大事件(修正)
美股SEC公告 ·  2024/08/06 18:09

Moomoo AI 已提取核心訊息

BioVie Inc., a Nevada-based biopharmaceutical company, has filed an amendment to its previous Current Report on Form 8-K with the Securities and Exchange Commission. The amendment, dated August 1, 2024, pertains to the company's reverse stock split that was initially reported on July 31, 2024. The recent filing includes the Certificate of Termination and the Certificate of Amendment related to the one-for-ten reverse stock split of BioVie's common stock. The Certificate of Amendment, filed on August 2, 2024, corrected a defect in the original filing, while the Certificate of Termination, filed on August 5, 2024, nullified the initial Certificate of Change. Despite these administrative adjustments, there were no substantive changes to the terms or the timing of the reverse stock split as previously disclosed. The documents related to these filings, including the Certificate of Termination and the Certificate of Amendment, have been provided as exhibits under Item 9.01 in the amended report.
BioVie Inc., a Nevada-based biopharmaceutical company, has filed an amendment to its previous Current Report on Form 8-K with the Securities and Exchange Commission. The amendment, dated August 1, 2024, pertains to the company's reverse stock split that was initially reported on July 31, 2024. The recent filing includes the Certificate of Termination and the Certificate of Amendment related to the one-for-ten reverse stock split of BioVie's common stock. The Certificate of Amendment, filed on August 2, 2024, corrected a defect in the original filing, while the Certificate of Termination, filed on August 5, 2024, nullified the initial Certificate of Change. Despite these administrative adjustments, there were no substantive changes to the terms or the timing of the reverse stock split as previously disclosed. The documents related to these filings, including the Certificate of Termination and the Certificate of Amendment, have been provided as exhibits under Item 9.01 in the amended report.
總部位於內華達州的生物醫藥公司BioVie已向證券交易所提交了原先在8-k表格上的修正變更報告。這份於2024年8月1日發佈的修正版關於該公司7月31日最初報告的股票拆分的內容。最近提交的文件中包括BioVie普通股進行一比十拆股的終止證明書和修正證書。修正證書於2024年8月2日提交,矯正了原始提交中的缺陷,而終止證書於2024年8月5日提交,廢除了最初的變更證明。儘管進行了這些行政調整,但與先前披露的股票拆分的條款或時間沒有實質性變化。與這些申報有關的文件,包括終止證明書和修正證明書,已作爲附件在修改後的報告中提供,屬於9.01項。
總部位於內華達州的生物醫藥公司BioVie已向證券交易所提交了原先在8-k表格上的修正變更報告。這份於2024年8月1日發佈的修正版關於該公司7月31日最初報告的股票拆分的內容。最近提交的文件中包括BioVie普通股進行一比十拆股的終止證明書和修正證書。修正證書於2024年8月2日提交,矯正了原始提交中的缺陷,而終止證書於2024年8月5日提交,廢除了最初的變更證明。儘管進行了這些行政調整,但與先前披露的股票拆分的條款或時間沒有實質性變化。與這些申報有關的文件,包括終止證明書和修正證明書,已作爲附件在修改後的報告中提供,屬於9.01項。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息